CNSP (CNS Pharmaceuticals Inc) סך כל נכסי החברה

The price chart on GURU.Markets illustrates the dynamics of total assets, which currently stand at 18.22, correlating with high medical testing expenses and a lack of economies of scale in R&D. CNS Pharmaceuticals (CNSP) is developing a blood-brain barrier-penetrating anthracycline for the treatment of glioblastoma. The business relies on the exclusivity of Berubicine, ensuring stable sales due to the absence of analogues.

CNS Pharmaceuticals' development of innovative neuro-oncology drugs requires significant resources; therefore, the aggregate of capital and liabilities, reverse-calculated via ROA, reflects the actual scale of the company's material base. This metric measures the financial equilibrium between R&D investments and debt load, allowing investors to assess the balance between operational stability and the risk of profit shortfall through the value of the company's financial assets.